Publications by authors named "Celia Lobo Romero"
Article Synopsis
Candida auris is a growing concern due to its resistance to antifungal drugs, particularly amphotericin B (AMB), detected in 30 to 60% of clinical isolates. However, the mechanisms of AMB resistance remain poorly understood. Here we investigated 441 in vitro- and in vivo-evolved C.
View Article and Find Full Text PDFArticle Synopsis
- Antifungal drug resistance is a significant global health issue, prompting the need for new treatment strategies that involve understanding collateral sensitivity and cross-resistance in pathogenic fungi.
- A study on Candida auris revealed that using collateral sensitivity-based drug cycling can effectively prevent drug resistance from developing and can help eliminate resistant sub-populations.
- The findings indicate that incorporating collateral sensitivity into treatment decisions could lead to better antifungal therapies, as certain sensitivity trends appear consistent across different strains and resistance mechanisms.
Article Synopsis
- An opportunistic pathogenic yeast has emerged worldwide over the past decade, posing a significant public health threat due to multidrug resistance (MDR) and frequent hospital outbreaks.
- Genomic studies have identified five distinct clades of this yeast, which vary in virulence and drug resistance and are tied to different geographic regions.
- The development of five allele-specific PCR assays allows for quick and affordable identification of these clades, offering a valuable tool for understanding outbreaks and potential drug resistance without needing extensive sequencing.
is an opportunistic human fungal pathogen and is frequently present in the human microbiome. It has a high relative resistance to environmental stresses and several antifungal drugs. An important component involved in microbial stress tolerance is trehalose.
View Article and Find Full Text PDFPublic health problems are associated with device-associated biofilm infections, with being the major fungal pathogen. We previously identified potent antibiofilm combination treatment in which the antifungal plant defensin HsAFP1 is co-administered with caspofungin, the preferred antimycotic to treat such infections. In this study, we identified the smallest linear HsAFP1-derived peptide that acts synergistically with caspofungin or anidulafungin against as HsLin06_18, a 19-mer peptide derived from the C-terminal part of HsAFP1.
View Article and Find Full Text PDF